Cardiorenal disease is commonly the first cardiovascular disease (CVD) manifestation in patients with type 2 diabetes (T2D) without a history of CVD disease, significantly increasing risk for all-cause mortality in this patient population, according to study results presented at the 55th Annual Meeting of the European Association for the Study of Diabetes, held September 16 to 20, 2019, in Barcelona, Spain. Using healthcare insurance claims registries in Germany and Japan and full population registries from Norway and Sweden, researchers collected data from patients with T2D without a history of CVD or chronic kidney disease (CKD; n=687,732) Continue reading →

BARCELONA Results of the landmark DAPA-HF trialshowing that the glucose-lowering drug dapagliflozin (Farxiga, AstraZeneca) provides "quite stunning, pretty consistent benefit" in patients with heart failure, both with and without type 2 diabetes, were published online September 19 in the New England Journal of Medicine. Continue reading →

In patients with transient ST-segment elevation myocardial infarction (STEMI), both delayed invasive treatment and immediate invasive treatment result in similar good clinical outcomes 1 year later, according to study results published in JACC Cardiovascular Interventions. The study included a total of 142 patients age > 18 (mean age, 61.711.3) years, who presented with an acute STEMI with complaints of any duration and ST-segment elevations 2 mm in 2 standard limb leads or 2 contiguous chest leads during a prehospital electrocardiogram. The patients also had to exhibit spontaneous, complete resolution of ST-segment elevation and complete relief of symptoms with or without treatment Continue reading →

In the United States, proton pump inhibitors (PPIs) are one of the most widely used classes of drugs and are the most effective drugs for treating Gastroesophageal reflux disease (GERD). Continue reading →

Ryan M. Ridenour CHICAGO Preoperative opioid exposure was linked with significant perioperative consequences and postoperative complications in patients who underwent foot and ankle surgery, according to a presenter at the American Orthopaedic Foot & Ankle Society Annual Meeting Continue reading →

PARIS Dual therapy with the novel oral anticoagulant (NOAC) edoxaban (Savaysa, Daiichi Sankyo) and a P2Y12 inhibitor was noninferior to triple therapy with a vitaminK antagonist, a P2Y12 inhibitor, and aspirin to prevent major bleeding after successful stenting in patients with atrial fibrillation (AF). The P2Y12 inhibitor was clopidogrel (Plavix, Sanofi) in 93% of the patients, and rarely ticagrelor (Brilinta/Brilique, AstraZeneca) or prasugrel (Effient, Lilly/Daiichi Sankyo). Andreas Goette Andreas Goette, MD, professor and head, Department of Cardiology and Intensive Care Medicine, St.Vincenz Hospital, Paderborn, Germany, presented results from the Edoxaban Treatment Versus VitaminK Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI) trial during a press briefing and a hotline session here at the European Society of Cardiology Congress 2019 Continue reading →

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed (ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco from September 25-29. During the conference, Abiomed will also offer hands-on training to help physicians improve access and closure skills and patient management expertise to achieve improved outcomes. This press release features multimedia. Continue reading →

A profound analysis of the industry based on the "Myocardial Infarction Drug Market" all over the world is named as Global Myocardial Infarction Drug Market Report. The research report assesses the current as well as the upcoming performance of the Myocardial Infarction Drug market, in addition to with newest trends in the market Continue reading →